Search
for
Sort by
Research 30 of 229
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
- Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- A review of Janus kinase inhibitor use in scarring alopecia
- Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
- Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib
- Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
- Deucravacitinib in dermatology: current indication and existing off-label data
- Review of Promising Off-Label Use of Deucravacitinib
- Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
- 700 Tyrosine kinase 2 inhibition rescues hair follicles from IL-12–mediated immune privilege collapse and reverses the induction of human alopecia areata in a humanized mouse model
- Modern Therapies for Discoid Lupus Erythematosus: A Narrative Review
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- Discoid lupus erythematosus successfully treated with deucravacitinib
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- 061 Selective inhibition of tyrosine kinase 2 prevents and restores interleukin-12-induced hair follicle immune privilege collapse: a novel approach to alopecia areata therapy?
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- 014 Tyrosine Kinase 2 Inhibition Ameliorates the Phenotype of Lesional Alopecia Areata Scalp Skin Ex Vivo, and Reverses the Induction of Human Alopecia Areata in a Humanized Mouse Model
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Janus Kinase inhibitors in dermatology: a review
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- The Role of Janus Kinase Inhibitors in Dermatology
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata